Poor
Not Aligned
Patient Risk:
Low
Summary
The statements provided are primarily about patent coverage, pricing, and insurance/coverage processes, which are not addressed in the supplied FDA-approved prescribing information excerpts. No label-supported claims can be confirmed, and many assertions are therefore unsupported by the provided label text.
Category Scores
Accurate Statements
Ubrelvy (rimegepant) is a branded prescription product.
Not supported or contradicted by the provided label excerpts.
Ubrelvy’s price is driven in part by how new and still-protected migraine medicines are marketed and priced.
Not supported or contradicted by the provided label excerpts.
Unsupported Statements
Patent coverage and regulatory exclusivity can delay generic or biosimilar competition for Ubrelvy.
Not addressed in the provided FDA prescribing information excerpts.
When exclusivity is still in effect, manufacturers can set higher prices with less pressure from lower-cost versions.
Not addressed in the provided FDA prescribing information excerpts.
Ubrelvy’s price is driven in part by how new and still-protected migraine medicines are marketed and priced.
Not addressed in the provided FDA prescribing information excerpts.
As a newer branded therapy, Ubrelvy typically carries higher brand pricing than established generics.
Not addressed in the provided FDA prescribing information excerpts.
Limited cost competition can occur for Ubrelvy depending on what insurers cover.
Not addressed in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Ubrelvy can be affected by plan coverage rules.
Not addressed in the provided FDA prescribing information excerpts.
Plan coverage rules can include preferred tier placement, prior authorization requirements, and coverage only for certain diagnoses.
Not addressed in the provided FDA prescribing information excerpts.
Insurers may restrict or control access through utilization management even when a medicine is clinically used for migraine.
Not addressed in the provided FDA prescribing information excerpts.
Common reasons patients face high costs include prior authorization requirements not being met or being delayed.
Not addressed in the provided FDA prescribing information excerpts.
Common reasons patients face high costs include not having met deductibles.
Not addressed in the provided FDA prescribing information excerpts.
Common reasons patients face high costs include copays being higher for non-preferred branded drugs.
Not addressed in the provided FDA prescribing information excerpts.
Benefit design can make Ubrelvy costly on certain tiers.
Not addressed in the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
Any on-label clinical content relevant to the product label excerpts (e.g., indicated use, recommended dosing limits, contraindications, or safety warnings) is not provided in the AI statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No dosing, contraindication, interaction, or safety claims were made that could directly conflict with the provided prescribing information excerpts; however, the content is largely unrelated to label-based clinical safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI statements focus on pricing/coverage/patent exclusivity and do not map to any provided FDA label content; therefore they are unsupported by the supplied prescribing information excerpts.
Suggested Improvement
Limit statements to information present in the FDA-approved prescribing information (e.g., acute migraine indication and limitation of use, recommended dosing and maximum dose, contraindications with strong CYP3A4 inhibitors, warnings/precautions such as hypersensitivity/ hypertension/Raynaud’s, and labeled drug interaction guidance).